
REMARKS

This paper is filed concurrently with the application papers requesting filing and immediate examination of a United States national application based on international application no. PCT/US2003/022925, filed July 23, 2003, claiming priority to US provisional application 60/397,834 filed July 23, 2002 and US provisional application 60/427,488 filed November 19, 2002. Please enter the foregoing amendments prior to calculation of the filing fee and prior to examination on the merits.

The first paragraph of the specification has been amended herein to provide updated information regarding cross-reference to related applications under 37 C.F.R. § 1.78. Pages 1 and 60 have been amended to insert SEQ ID NO: designations. Additionally, Applicants have amended page 82 of the specification to correct an obvious typographical error in the ghrelin analog formula:

"(Aib², Glu³(NH-Hexyl), A5c^{5,12}, Apc¹⁶)hGhrelin(1-28)-NH₂" is correct to read

"(Aib², Glu³(NH-Hexyl), A5c^{5,12}, Apc¹⁶)hGhrelin(1-28)-NH₂".

Claim 4 was similarly amended to correctly recite "A5c^{5,12}".

Claim 1 has been amended to remove the duplicated "Act" moiety stated in the definition of A².

Claims 2-8 and 10-13 have been amended to further specify "or a pharmaceutically acceptable salt thereof". Support for the amendment is apparent from generic Claim 1, from which Claims 2-8 and 10-13 ultimately depend.


Additionally, Claims 14-16, 21, 22, 27, 31, and 35 have been amended to depend from Claim 1 only.

No new matter is added by these amendments.

A check (No. 6124) in the amount of \$2150.00 to cover the national stage filing fees accompanies these papers, and the fees are calculated taking the foregoing amendments into account, since the amendments eliminate some multiple dependencies from the claims. No additional fees are believed to be due; however, the Commissioner is specifically authorized to charge any additional fees deemed to be necessary in connection with the filing of this paper or any of the accompanying papers, or to charge other fees necessary to complete this US filing to Deposit Account 50-0268.

Entry of the foregoing amendments and examination of the claims as amended are requested.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Leon R. Yankwich". The signature is fluid and cursive, with the first name "Leon" and last name "Yankwich" clearly distinguishable.

Leon R. Yankwich, Reg. No. 30,237
Michael R. Wesolowski, Reg. No. 50,944
Attorneys for Applicant
YANKWICH & ASSOCIATES, P.C.
201 Broadway
Cambridge, Massachusetts 02139
telephone: 617-374-3700
telecopier: 617-374-0055